Investor Presentaiton

Non-GAAP Measures The Bank uses a number of financial measures to assess its performance. Some of these measures are not calculated in accordance with Generally Accepted Accounting Principles (GAAP), which are based on International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board (IASB), are not defined by GAAP and do not have standardized meanings that would ensure consistency and comparability among companies using these measures. The Bank believes that certain non-GAAP measures are useful in assessing ongoing business performance and provide readers with a better understanding of how management assesses performance. These non-GAAP measures are used throughout this report and defined below. Adjusted results and diluted earnings per share The following table presents reconciliations of GAAP Reported financial results to non-GAAP Adjusted financial results. The adjustments summarized below are consistent with those described in the Bank's 2020 Annual Report. For a complete description of the adjustments, refer to the Non-GAAP Measures section in the Bank's 2020 Annual Report: 1) Adjustments impacting current and prior periods: Acquisition-related costs Amortization of Acquisition-related intangible assets, excluding software - Includes amortization of intangible assets relating to prior period acquisitions. 2) Adjustments impacting prior periods: Acquisition and divestiture-related amounts Acquisition-related costs Integration costs - Includes costs that are incurred and relate to integrating acquired operations. Net (gain)/loss on divestitures - Includes net (gain)/loss on divestitures undertaken in accordance with the repositioning strategy of the Bank. (refer to Note 20 in the Q1/21 Shareholder's Report for further details). Valuation-related adjustments Includes: (i) increase in allowance for credit losses (ACL) associated with the addition of an additional, more severe pessimistic scenario to the ACL measurement methodology; (ii) Charge related to the enhancement of fair value methodology relating to uncollateralized OTC derivatives; and (iii) impairment loss related to a software asset. These adjustments were recorded in Q1, 2020. 37

View entire presentation